The reimbursement of a digital therapeutic has just reached an unprecedented milestone in France. On 2 April 2026, the National Committee for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS), part of the French National Authority for Health (HAS), issued its very first favourable opinion on the reimbursement of a digital therapeutic. The solution in question, named Joe and developed by the company Ludocare, is designed for children aged 7 to 11 with persistent asthma. It is a decision the digital medical device sector had been waiting for over several years, and one that could durably change market access in France for this type of solution. Until now, digital therapeutics existed in a grey area: authorised for sale as medical devices, but without a sustainable business model due to the lack of reimbursement by French national health insurance. This first opinion closes that gap and finally gives digital health innovators a clear path forward.
What Is This First Favourable Opinion on the Reimbursement of a Digital Therapeutic?
Joe combines a small robot with a built-in screen and a companion app. The tool supports children in following their treatment through educational videos explaining how to take their medication and use their inhaler correctly. The goal is twofold: to build the young patient’s autonomy and to improve adherence to background treatment. It was this combination, judged clinically relevant by HAS, that made it possible to obtain this first favourable opinion on the reimbursement of a digital therapeutic in France.
Why This Reimbursement of a Digital Therapeutic Is a Turning Point
Until now, no digital therapeutic had demonstrated, in the eyes of the CNEDiMTS, enough clinical superiority to justify coverage by French health insurance. Ludocare’s file changes that: the data submitted show a significant reduction in asthma exacerbations among children using Joe, compared with standard care. This reimbursement of a digital therapeutic confirms, for the first time, that a purely software-based, interactive solution can be assessed, and reimbursed, under the same clinical evidence requirements as a more conventional medical device. For DTx developers as a whole, it is a major regulatory precedent, widely covered even by the specialist mental health press, which closely follows these questions of access to reimbursement for digital health solutions.
The Conditions Set by HAS for This Reimbursement of a Digital Therapeutic
This first favourable opinion does not yet mean an effective reimbursement: implementation still depends on a ministerial decree being published. HAS has also attached strict conditions to its decision. Over a period of twelve months, Ludocare will need to produce real-world data confirming, on a larger scale, the reduction in exacerbations and the improved adherence already observed during the initial evaluation. This demanding framework illustrates HAS’s philosophy on the reimbursement of a digital therapeutic: granting progressive trust, paired with rigorous post-listing follow-up, rather than a definitive validation without safeguards.
What’s Next for the Reimbursement of Digital Medical Devices?
Beyond the Joe case, this decision maps out a trajectory for the whole sector. HAS has indicated it intends to keep clarifying its evaluation doctrine through methodological publications and early meetings with project leads, to help future DTx developers anticipate what the committee expects. For manufacturers preparing a reimbursement of a digital therapeutic application, the lesson is clear: from the earliest clinical design stage, they need to build an evidence plan capable of demonstrating a measurable, reproducible benefit, not merely a perceived improvement in patient experience. This often means bringing together clinical teams, biostatisticians and regulatory experts very early on, so the evaluation protocol is designed to directly meet the criteria expected by the CNEDiMTS, rather than being adapted after the fact.
Reimbursement of a Digital Therapeutic: A Signal Worth Watching Closely
This first favourable opinion on the reimbursement of a digital therapeutic marks a turning point for France’s digital medical device ecosystem. It opens a path that other solutions, in asthma as well as in other chronic conditions, will likely try to follow in the coming months. For manufacturers and project leads, understanding precisely the criteria used by the CNEDiMTS is becoming as much a strategic issue as a regulatory one.
BluePharm closely follows these developments and supports medical device companies in producing up-to-date scientific and regulatory content, to help them understand and anticipate these structural changes in the digital health market.
